Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Spinal cord injuries are the injuries caused to the thirty one pairs of spinal nerves, which carry nerve signals from brain to various parts of the body and also controls the arms and leg movements. The main cause of spinal cord injuries include trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections. Spinal cord injuries can be diagnosed with the help of various techniques such as X-ray, magnetic resonance index (MRI), and computed tomography (CT).

The global spinal cord injury therapeutics market is estimated to be valued at US$ 6,630.7 million in 2020 and is expected to exhibit a CAGR of 6.7% during the forecast period (2020-2027).

Figure 1. Global Spinal Cord Injury Therapeutics Market Value (US$ Mn), 2016-2027

Spinal Cord Injury Therapeutics  | Coherent Market Insights

Increasing prevalence of traumatic spinal cord injuries is expected to propel growth of the global spinal cord injuries therapeutics market during the forecast period. For instance, according to the US National Library of Medicine report published in 2018, stated that the prevalence of traumatic spinal cord injuries in low and middle economic economies such as Algeria, Bangladesh etc was 8.72 % per 100,000 individuals and prevalence of traumatic spinal cord injuries in high income countries such as Bermuda (UK), Switzerland and others was 13.69 % per 100,000 individuals, globally in the year 2018.

Furthermore, key companies focusing on research and development in the treatment of spinal cord injury is expected to propel growth of the global spinal cord injury therapeutics market during the forecast period. For instance, in July 2017, ReNetX Bio, licensed the rights of the innovative neuro-restorative Nogo Receptor platform technology developed at Yale University. The central nervous system contains major extracellular factors that limit the regrowth of neurons. The university developed a decoy receptor, called Nogo Trap that binds the growth inhibitors allowing the body to grow nerve fibers naturally.

request-sample

Spinal Cord Injury Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 6,630.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.7% 2027 Value Projection: US$ 9,239.1 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Injury Type: Complete Spinal Cord Injury, Incomplete Spinal Cord Injury.
  • By Drug Type: Corticosteroids, Muscle Relaxants and Anti-spastic drugs, Non-steroidal Anti-inflammatory drugs ( NSAID’S), Anti-depressants, Anticonvulsants, Others.
  • By Application: Autonomic Dysreflexia (AD), Spasticity & Inflammation, Pain Management, Depression.
  • By Route of Administration: Oral, Intravenous.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

ReNetX Bio, InVivo Therapeutics Hldg, GTX Medical, Acorda Therapeutics, Lineage Cell Therapeutics, AbbVie Inc., Asterias Biotherapeutics, Inc, BioArctic, Kringle Pharma, Inc., Pfizer Inc., Pharmicell Co., Ltd., Bioaxone Biosciences, Inc., Vertex Pharmaceuticals Inc., Biogen Inc., RespireRx Phamaceuticals Inc., NervGen, Lannett Co Inc, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, MSN Laboratories Private Limited, Rising Pharmaceuticals, Inc., ScieGen Pharmaceuticals, Inc, and Cadila Healthcare Limited.

Growth Drivers:
  • Increasing prevalence of spinal cord injury globally
  • Increasing clinical trials by key players and academic institutes
Restraints & Challenges:
  • Expenses associated with spinal cord injury management & treatment

Global Spinal Cord Injury Therapeutics Market – Impact of Coronavirus (COVID-19)

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in over 60.9 million infected individuals worldwide as of 27th November, 2020.

Covid-19 pandemic has affected the spinal cord injury therapeutics market negatively in various ways such as shortage of personal healthcare attendant and health care treatments for individuals suffering from spinal cord injuries. Therefore various academic institutes and companies are taking initiatives to combat various difficulties faced by individuals such as shortage of personal healthcare attendant and health care treatments for individuals suffering from spinal cord injuries during the COVID-19 pandemic. For instance, in May 2020, United Spinal Association, a nonprofit membership, disability rights, and veterans service organization initiated one on one assistance provided by United Spinal’s team of information specialists to the individuals suffering from spinal cord injuries and various difficulties faced by them due to COVID-19 pandemic.  

Figure 2. Global Spinal Cord Injury Therapeutics Market Share (%), By Region, 2020

Spinal Cord Injury Therapeutics  | Coherent Market Insights

North America is expected to hold dominant position in the global spinal cord injuries therapeutics market during the forecast period, owing to key companies focusing on research and development for the treatment of spinal cord injury. For instance, in 2018, Vertex Pharmaceuticals Incorporated, a U.S.-based biopharmaceutical company completed the investigational clinical trial study on the safety and efficacy of VX-210 in 70 subjects with acute traumatic cervical spinal cord injury and also had secondary objective, which included the specific evaluation of the effects of VX-210 on neurological recovery and daily function after spinal cord injury.

Key Players

Major players operating in the global spinal cord injury therapeutics market include ReNetX Bio, InVivo Therapeutics Hldg, GTX Medical, Acorda Therapeutics, Lineage Cell Therapeutics, AbbVie Inc., Asterias Biotherapeutics, Inc, BioArctic, Kringle Pharma, Inc., Pfizer Inc., Pharmicell Co., Ltd., Bioaxone Biosciences, Inc., Vertex Pharmaceuticals Inc., Biogen Inc., RespireRx Phamaceuticals Inc., NervGen, Lannett Co Inc, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, MSN Laboratories Private Limited, Rising Pharmaceuticals, Inc., ScieGen Pharmaceuticals, Inc, and Cadila Healthcare Limited.

The global spinal cord injury therapeutics market comprises therapeutics used for the treatment of spinal cord injury. There are various therapeutics such as corticosteroids, non-steroidal anti-inflammatory drugs (NSAID’S), muscle relaxants and anti-depressants. There are two types of spinal cord injuries such as complete spinal cord injury and incomplete spinal cord injury and various causes of spinal cord injuries include brain injury, trauma, loss of blood supply to spinal cord, and compression in spinal cord due to tumor or infections.

Market Dynamics

Key players are focusing on product approvals to strengthen their position in the global spinal cord injury therapeutics market. For instance, in September 2020, AbbVie, received an orphan drug and fast track designation from the U.S. Food and Drug Administration for Elezanumab, an investigational monoclonal antibody RGMa inhibitor for the treatment of spinal cord injury.

Key features of the study:

  • This report studies the current scenario as well as the future potential of the global spinal cord injury therapeutics market. The market for spinal cord injury therapeutics is segmented on basis of injury type, drug type, application, route of administration, distribution channel, and region.
  • This report provides in-depth analysis of the global spinal cord injury therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020–2027)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by leading players.
  • It profiles leading players in the global spinal cord injury therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
  • The global spinal cord injury therapeutics market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global spinal cord injury therapeutics market

Detailed Segmentation:

  • Global Spinal Cord Injury Therapeutics Market, By Injury Type:
    • Complete Spinal Cord Injury
    • Incomplete Spinal Cord Injury
  • Global Spinal Cord Injury Therapeutics Market, By Drug Type:
    • Corticosteroids
    • Muscle Relaxants and Anti-spastic drugs
    • Non-steroidal Anti-inflammatory drugs ( NSAID’S)
    • Anti-depressants
    • Anticonvulsants
    • Others
  • Global Spinal Cord Injury Therapeutics Market, By Application:
    • Autonomic Dysreflexia (AD)
    • Spasticity & Inflammation
    • Pain Management
    • Depression
  • Global Spinal Cord Injury Therapeutics Market, By Route of Administration :
    • Oral
    • Intravenous
  • Global Spinal Cord Injury Therapeutics Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Spinal Cord Injury Therapeutics Market, By Region:
    • North America
      • By Injury Type:
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type:
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs ( NSAID’S)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application:
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Injury Type:
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type:
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs ( NSAID’S)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application:
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Injury Type:
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type:
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs ( NSAID’S)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application:
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Injury Type:
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type:
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs ( NSAID’S)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application:
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Injury Type:
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type:
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs ( NSAID’S)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application:
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Injury Type:
        • Complete Spinal Cord Injury
        • Incomplete Spinal Cord Injury
      • By Drug Type:
        • Corticosteroids
        • Muscle Relaxants and Anti-spastic drugs
        • Non-steroidal Anti-inflammatory drugs ( NSAID’S)
        • Anti-depressants
        • Anticonvulsants
        • Others
      • By Application:
        • Autonomic Dysreflexia (AD)
        • Spasticity & Inflammation
        • Pain Management
        • Depression
      • By Route of Administration:
        • Oral
        • Intravenous
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • ReNetX Bio.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • InVivo Therapeutics Hldg
    • GTX Medical
    • Acorda Therapeutics
    • Lineage Cell Therapeutics
    • AbbVie Inc.
    • Asterias Biotherapeutics, Inc
    • BioArctic
    • Kringle Pharma, Inc.
    • Pfizer Inc.
    • Pharmicell Co., Ltd.
    • Bioaxone Biosciences, Inc.
    • Vertex Pharmaceuticals Inc.
    • Biogen Inc.
    • RespireRx Phamaceuticals Inc.
    • NervGen
    • Lannett Co Inc
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories
    • MSN Laboratories Private Limited
    • Rising Pharmaceuticals, Inc.
    • ScieGen Pharmaceuticals, Inc
    • Cadila Healthcare Limited

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Injury Type
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Application 
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunities
    • Impact Analysis
    • Key Developments
    • New Product Launches/Approvals
    • Merger-Acquisition Scenario
    • Regulatory Scenario
    • Pipeline Analysis
    • Epidemiology
    • PEST Analysis
    • Reimbursement
  4. Global Spinal Cord Injury Therapeutics Market - Impact of COVID-19 Pandemic
    • Government Initiative To Combat Covid-19
    • COVID 19 Impact on Overall Healthcare Market
    • COVID 19 Impact on Spinal Cord Market
  5. Global Spinal Cord Injury Therapeutics Market, By Injury Type, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        •  Complete Spinal Cord Injury
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Incomplete Spinal Cord Injury
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Spinal Cord Injury Therapeutics Market, By Drug Type, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        •  Corticosteroids
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Muscle Relaxants and Anti-spastic drugs
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Non-steroidal Anti-inflammatory drugs ( NSAID’S)
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Anti-depressants
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Anticonvulsants
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Global Spinal Cord Injury Therapeutics Market, By Application, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        •  Autonomic Dysreflexia (AD)
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Spasticity & Inflammation
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Pain Management
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Depression
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  8. Global Spinal Cord Injury Therapeutics Market, By Route of Administration, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Oral
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Intravenous
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  9. Global Spinal Cord Injury Therapeutics Market, By Distribution Channel, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Retail Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Online Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  10. Global Spinal Cord Injury Therapeutics Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Injury Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Injury Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Injury Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Injury Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Injury Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Injury Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  11. Competitive Landscape
    • Company Profiles
      • ReNetX Bio
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • InVivo Therapeutics Hldg
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GTX Medical
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Acorda Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lineage Cell Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Asterias Biotherapeutics, Inc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BioArctic
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Kringle Pharma, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pharmicell Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bioaxone Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Vertex Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Biogen Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • RespireRx Phamaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • NervGen
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lannett Co Inc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Dr. Reddy's Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • MSN Laboratories Private Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Rising Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ScieGen Pharmaceuticals, Inc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cadila Healthcare Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 33 market data tables and 32 figures on " Spinal Cord Injury Therapeutics Market – Global forecast to 2027”.

Frequently Asked Questions

The global spinal cord injury therapeutics market size is estimated to be valued at US$ 6,630.7 million in 2020 and is expected to exhibit a CAGR of 6.7% between 2020 and 2027.
Increasing prevalence of spinal cord injury globally and increasing clinical trials by key players and academic institutes are expected to drive growth of the global spinal cord injury therapeutics market.
Complete spinal cord injury segment is estimated to hold major market share in the global spinal cord injury therapeutics market during the forecast period, owing to an increasing prevalence of complete spinal cord injury in individuals globally.
Corticosteroids segment is estimated to hold major market share in the global spinal cord injury therapeutics market during the forecast period, owing to key companies focusing on treatment of spinal cord injuries with the corticosteroids due to its efficacy.
North America is estimated to generate largest revenue share in 2020 in the global spinal cord injury therapeutics market.
Expenses associated with spinal cord injury management & treatment are the key factors that are expected to hamper growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner